Progressive Supranuclear Palsy News and Research

RSS

Low accuracy of clinical diagnosis for early Parkinson’s disease

About three-quarters of patients suspected to have early Parkinson’s disease eventually prove to have other conditions, a study shows.

3 Jul 2014

Bristol-Myers Squibb completes acquisition of iPierian

Bristol-Myers Squibb Company and iPierian, Inc. announced today that Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

29 Apr 2014

Study suggests promising brain-imaging technique to improve diagnoses of people with movement disorders

A new University of Florida study suggests a promising brain-imaging technique has the potential to improve diagnoses for the millions of people with movement disorders such as Parkinson's disease.

14 Jun 2013

Mouse study shows leukemia halts accumulation of toxic proteins linked to Parkinson's disease

Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects.

10 May 2013

New model of tau pathology spread

Brain diseases associated with the misformed protein tau, including Alzheimer's disease and frontotemporal lobar degeneration with tau pathologies, are characterized by neurofibrillary tangles (NFTs) comprised of pathological tau filaments.

19 Jan 2013

Palliative care needs expanding

Individuals with late-stage Parkinson's disease and other related motor disorders experience severe symptoms of physical and psychologic distress, suggesting that current care is falling short, say UK researchers.

29 Nov 2012

Allon Files Preliminary Shelf Prospectus

Allon Therapeutics Inc. has filed a preliminary short form base shelf prospectus with the securities commissions in each province and territory of Canada (other than Quebec).

23 Nov 2012

Study shows how Parkinson's spreads and leads to nerve cell death

Understanding how any disease progresses is one of the first and most important steps towards finding treatments to stop it. This has been the case for such brain-degenerating conditions as Alzheimer's disease. Now, after several years of incremental study, researchers at the Perelman School of Medicine, University of Pennsylvania have been able to piece together important steps in how Parkinson's disease (PD) spreads from cell to cell and leads to nerve cell death.

17 Nov 2012

Closing in on neurologic biomarker diagnosis

A panel of five cerebrospinal fluid biomarkers may help doctors to accurately diagnose patients with various forms of dementia and parkinsonian disorders, research published in the Archives of Neurology suggests.

30 Aug 2012

Grape-derived compound may prevent neurodegenerative disorders involving tau neuropathology

Researchers at Mount Sinai School of Medicine have gained insight into the mechanism by which a pathological brain protein called tau contributes to the progression of Alzheimer's disease (AD) and other neurodegenerative disorders. This finding, published in the most recent issue of the Journal of Biological Chemistry, may provide the basis for future investigations on how to prevent tau from damaging brain circuits involved in cognitive function.

2 May 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

DaTscan aids doctors in diagnosing patients with Parkinson's disease

Fifty thousand to 60,000 new cases of Parkinson's disease are diagnosed in the United States each year. Central DuPage Hospital (CDH) in Winfield, Ill., is among the first medical centers in North America to be using a new technology called DaTscan, an imaging tool that aids doctors in diagnosing patients who demonstrate Parkinsonian symptoms, like Parkinson's disease.

29 Sep 2011

Scientists discover three susceptibility genes for development of progressive supranuclear palsy

An international research team, co-led by scientists at Mayo Clinic's campus in Florida, have discovered three potential susceptibility genes for development of progressive supranuclear palsy (PSP), a rare neurodegenerative disease that causes symptoms similar to those of Parkinson's disease but is resistant to Parkinson's medications.

20 Jun 2011

New insight into progressive supranuclear palsy

There are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

20 Jun 2011

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, announces that the U.S. Food and Drug Administration has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy.

9 May 2011

Neuropathologist receives AAN Potamkin Prize for Alzheimer's disease research

The American Academy of Neurology has awarded the 2011 Potamkin Prize to Dennis Dickson, M.D., a neuropathologist at Mayo Clinic in Florida and the Robert E. Jacoby Professor for Alzheimer's Disease Research.

3 Mar 2011

Noscira receives FDA approval for Tideglusib drug to treat PSP

Noscira, a Grupo Zeltia subsidiary specialized in research and development of drugs to treat neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to its neuroprotector drug Tideglusib (ZentylorTM) to treat Progressive Supranuclear Palsy (PSP), a fast-advancing fatal degenerative brain disorder.

10 Sep 2010